PDCD1 and urothelial carcinoma: Melanoma patients reported the greatest percentage of rash incidence during anti-PD-1 therapy (13.1 %, 95 % CI 12.1%–14.1 %), whereas nearly one-fifth of patients with urothelial carcinoma reported experiencing pruritis (19.0 %, 95 % CI 16.7%–21.6 %).